Company Filing History:
2 out of 633 
2 out of 2 Years Active: 2021-2025
Title: Ambili Kuniyil: Innovator in Protein Nanocages
Introduction
Ambili Kuniyil is a notable inventor based in Singapore, SG. He has made significant contributions to the field of biomedical engineering, particularly in the development of innovative therapeutic solutions. With a total of 2 patents, his work focuses on targeting melanocytes for delivering therapeutic or diagnostic agents.
Latest Patents
Ambili Kuniyil's latest patents include the invention titled "Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages." This invention relates to protein nanocages that comprise a melanocyte-targeting moiety and pharmaceutical compositions. These compositions are designed for treating or diagnosing hyperpigmentation disorders or other melanocyte-related disorders. The preferred embodiment of the protein nanocage is composed of the E2 protein of the pyruvate dehydrogenase multi-enzyme complex, featuring a skin-penetrating and cell-permeating SPACE moiety, along with a melanocyte-targeting moiety derived from alpha melanocyte-stimulating hormone.
Career Highlights
Throughout his career, Ambili Kuniyil has worked with esteemed institutions such as Nanyang Technological University and the National Skin Center Pte Ltd. His research and innovations have contributed to advancements in the understanding and treatment of skin-related conditions.
Collaborations
Ambili has collaborated with notable colleagues, including Sierin Lim and Sathyamoorthy Bhaskar, who have played a role in his research endeavors.
Conclusion
Ambili Kuniyil's work in the field of protein nanocages represents a significant advancement in therapeutic delivery systems. His innovative approach to targeting melanocytes has the potential to improve treatment options for various skin disorders.